Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. David Alan Campbell Ph.D. | President, CEO & Director | 1.04M | -- | 1960 |
| Mr. Charles M. Winter | Chief Technical Officer | 590.4k | -- | 1969 |
| Mr. Byron Robinson J.D., Ph.D. | Chief Strategy Officer | 723k | -- | 1965 |
| Mr. Matt Whitmire | Vice President of Finance | -- | -- | -- |
| Ms. Maria Dobek | Principal Accounting Officer & VP of Accounting | -- | -- | 1990 |
| Dr. Tommy Diraimondo Ph.D. | Chief Scientific Officer | -- | -- | 1986 |
| Mr. James Pennington | General Counsel | -- | -- | -- |
| Mr. Andy Hollman Meyer | Chief Business Officer | -- | -- | 1984 |
| Dr. Zachariah McIver D.O., Ph.D. | Chief Medical Officer | -- | -- | -- |
Janux Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 81
Description
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Corporate Governance
Upcoming Events
May 5, 2025 at 8:00 PM UTC - May 10, 2025 at 8:00 PM UTC
Janux Therapeutics, Inc. Earnings Date